Family Capital Trust Co Takes $1.97 Million Position in AbbVie Inc. $ABBV

Family Capital Trust Co purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, HoldingsChannel reports. The fund purchased 8,493 shares of the company’s stock, valued at approximately $1,966,000.

Other large investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $4,288,200,000. Laurel Wealth Advisors LLC lifted its position in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock worth $804,116,000 after buying an additional 3,666,521 shares during the period. Vanguard Group Inc. increased its position in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in shares of AbbVie in the second quarter valued at $581,817,000. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on ABBV. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Piper Sandler restated an “overweight” rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Evercore ISI lifted their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, BMO Capital Markets boosted their target price on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $246.89.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline/clinical progress — AbbVie advanced its icalcaprant (depression) Phase 2 program, which supports medium‑term pipeline optionality beyond its core immunology/oncology franchises. AbbVie Advances Icalcaprant Trial in Depression: What Investors Should Watch
• Positive Sentiment: Early‑stage oncology expansion — AbbVie launched a first‑in‑human trial for ABBV‑901 in ovarian cancer, increasing optional upside if the program shows early signal. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Positive Sentiment: Analyst support — Berenberg issued a buy on ABBV, giving some near‑term credibility to upside narratives and providing a buy signal for income/value investors. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Dividend/income appeal — commentary highlighting AbbVie’s yield and steady dividend profile is keeping income‑focused investors engaged despite valuation premium. AbbVie: The Dividend Does Not Lie
• Neutral Sentiment: Real‑world study readouts — post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped, which may gradually support label expansion and payer confidence but are not immediate revenue catalysts. AbbVie’s Korean Rinvoq Study in IBD Wraps Up, Setting the Stage for New Real‑World Data
• Neutral Sentiment: Upcoming results call — AbbVie set its full‑year and Q4 earnings release and Feb. 4 conference call; investors will watch guidance reconciliation and quarterly details for clarity. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Negative Sentiment: Guidance slightly below consensus — AbbVie trimmed/updated Q4 and FY‑2025 EPS ranges that sit at or just below street consensus, which likely pressured the stock as investors reprice near‑term growth expectations.
• Negative Sentiment: One‑time IPR&D/R&D charges — management flagged IPR&D and related expenses that will negatively impact Q4 EPS, creating near‑term earnings noise ahead of the February print. AbbVie sees negative Q4 EPS impact from IPR&D expenses
• Negative Sentiment: Failed takeover optimism — earlier media reports that AbbVie was in talks to buy Revolution Medicines briefly lifted sentiment; AbbVie subsequently denied talks, prompting disappointment and a reversal in momentum. AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

AbbVie Trading Down 3.9%

NYSE:ABBV opened at $224.22 on Friday. The firm has a fifty day simple moving average of $226.55 and a 200-day simple moving average of $214.86. The company has a market capitalization of $396.28 billion, a P/E ratio of 169.86, a PEG ratio of 0.98 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s payout ratio is currently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.